• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    7/11/22 2:37:37 PM ET
    $ADTX
    $BLI
    $BNR
    $CDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ADTX alert in real time by email

     

    Gainers

    • Pliant Therapeutics (NASDAQ:PLRX) stock moved upwards by 104.5% to $18.16 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 59.3 million shares, making up 20293.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $656.7 million.
    • La Jolla Pharmaceutical (NASDAQ:LJPC) stock rose 81.12% to $6.14. As of 13:30 EST, this security is trading at a volume of 4.6 million shares, making up 7878.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $156.9 million.
    • Iterum Therapeutics (NASDAQ:ITRM) stock increased by 71.62% to $0.41. As of 13:30 EST, Iterum Therapeutics's stock is trading at a volume of 131.3 million, which is 11264.9% of its average full-day volume over the last 100 days. The company's market cap stands at $75.5 million.
    • Genfit (NASDAQ:GNFT) stock increased by 18.44% to $4.06. As of 13:30 EST, this security is trading at a volume of 53.1K shares, making up 534.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $202.3 million.
    • Hillstream BioPharma (NASDAQ:HILS) stock moved upwards by 17.48% to $1.01. As of 13:30 EST, this security is trading at a volume of 1.0 million shares, making up 87.0% of its average full-day volume over the last 100 days. The company's market cap stands at $11.7 million.
    • Cidara Therapeutics (NASDAQ:CDTX) stock increased by 14.92% to $0.77. As of 13:30 EST, Cidara Therapeutics's stock is trading at a volume of 805.1K, which is 260.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $53.1 million.

    Losers

    • Aditxt (NASDAQ:ADTX) shares decreased by 17.4% to $0.2 during Monday's regular session. Trading volume for this security as of 13:30 EST is 17.1 million, which is 340.9% of its average full-day volume over the last 100 days. The company's market cap stands at $8.8 million.
    • Berkeley Lights (NASDAQ:BLI) stock decreased by 15.95% to $4.83. As of 13:30 EST, this security is trading at a volume of 852.2K shares, making up 84.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $327.2 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares decreased by 15.62% to $0.21. Trading volume for this security as of 13:30 EST is 6.3 million, which is 534.3% of its average full-day volume over the last 100 days. The company's market cap stands at $4.5 million.
    • Burning Rock Biotech (NASDAQ:BNR) stock fell 14.45% to $3.08. The current volume of 861.0K shares is 107.0% of Burning Rock Biotech's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $323.9 million.
    • Cardiff Oncology (NASDAQ:CRDF) shares fell 13.93% to $2.72. Trading volume for this security as of 13:30 EST is 720.2K, which is 68.7% of its average full-day volume over the last 100 days. The company's market cap stands at $117.7 million.
    • Freeline Therapeutics (NASDAQ:FRLN) shares decreased by 13.64% to $0.95. As of 13:30 EST, Freeline Therapeutics's stock is trading at a volume of 357.3K, which is 284.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $61.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $BLI
    $BNR
    $CDTX

    CompanyDatePrice TargetRatingAnalyst
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    Cidara Therapeutics Inc.
    $CDTX
    10/16/2025$190.00Overweight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    10/10/2025$200.00Overweight
    Analyst
    Pliant Therapeutics Inc.
    $PLRX
    10/10/2025Neutral → Underweight
    Analyst
    GENFIT S.A.
    $GNFT
    8/19/2025$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADTX
    $BLI
    $BNR
    $CDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dunne Michael W. bought $10,854 worth of Ordinary Shares (15,000 units at $0.72), increasing direct ownership by 7% to 235,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    8/12/25 7:00:06 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BLI
    $BNR
    $CDTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the reconvened special meeting held on February 13, 2026, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025877. As a r

    3/5/26 8:30:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.   TD Cowen 46th Annual Health Care ConferenceDate: 03/04/26 Barclays 28th Annual Global Healthcare ConferenceDate: 03/10/26 Leerink Partners Global Healthcare Conference 2026Date: 03/11/26 Interested parties can register for and access the live webcast for the conferences by visiting the "Events" section of the Cardiff Oncology website. The webcast replay will be available afte

    2/26/26 4:01:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

    Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an

    2/24/26 4:30:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $BLI
    $BNR
    $CDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Accounting Officer Lindsay Brigitte Ute

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    2/18/26 4:02:04 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Interim CEO Mohindru Mani

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    2/18/26 4:01:02 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Lindsay Brigitte Ute claimed ownership of 27,431 shares (SEC Form 3)

    3 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    2/9/26 4:00:10 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $BLI
    $BNR
    $CDTX
    SEC Filings

    View All

    Aditxt Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aditxt, Inc. (0001726711) (Filer)

    3/5/26 8:30:35 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics plc filed SEC Form 8-K: Other Events

    8-K - Iterum Therapeutics plc (0001659323) (Filer)

    3/3/26 4:45:24 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

    3/3/26 4:35:32 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BLI
    $BNR
    $CDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Cidara Therapeutics from Outperform to Sector Perform

    11/17/25 9:39:33 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cidara Therapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded Cidara Therapeutics from Overweight to Equal-Weight

    11/17/25 9:39:33 AM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $BLI
    $BNR
    $CDTX
    Financials

    Live finance-specific insights

    View All

    Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

    Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an

    2/24/26 4:30:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

    - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in the Journal of Clinical Oncology – - Onvansertib continues to be safe and well-tolerated – - Company expects to provide final data and registrational plans in first half of 2026 – - Company to h

    1/27/26 7:05:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iterum Therapeutics Reports Third Quarter 2025 Financial Results

    --Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. "We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs)," said

    11/14/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $BLI
    $BNR
    $CDTX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Burning Rock Announces Results of 2025 Annual General Meeting

    GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2025 be ratified and that the directors of the Company be authorized to d

    12/22/25 11:04:44 PM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

    GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 23, 2025 at 10:30 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The

    12/1/25 4:11:55 AM ET
    $BNR
    Medical Specialities
    Health Care

    $ADTX
    $BLI
    $BNR
    $CDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/3/24 4:34:49 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care